Davis HL - Search Results

1

CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Weeratna RD, McCluskie MJ, Xu Y, Davis HL. Weeratna RD, et al. Among authors: davis hl. Vaccine. 2000 Mar 6;18(17):1755-62. doi: 10.1016/s0264-410x(99)00526-5. Vaccine. 2000. PMID: 10699323

2

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85. doi: 10.1111/j.1574-695X.2002.tb00551.x. FEMS Immunol Med Microbiol. 2002. PMID: 11934561 Free article.

3

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.

Weeratna R, Comanita L, Davis HL. Weeratna R, et al. Among authors: davis hl. Immunol Cell Biol. 2003 Feb;81(1):59-62. doi: 10.1046/j.1440-1711.2003.01135.x. Immunol Cell Biol. 2003. PMID: 12534947

4

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. Weeratna RD, et al. Among authors: davis hl. Vaccine. 2005 Nov 1;23(45):5263-70. doi: 10.1016/j.vaccine.2005.06.024. Epub 2005 Jul 18. Vaccine. 2005. PMID: 16081189

5

Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.

Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH. Payette PJ, et al. Among authors: davis hl. Intervirology. 2006;49(3):144-51. doi: 10.1159/000089375. Intervirology. 2006. PMID: 16428890

6

DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice.

Davis HL, Brazolot Millan CL, Mancini M, McCluskie MJ, Hadchouel M, Comanita L, Tiollais P, Whalen RG, Michel ML. Davis HL, et al. Vaccine. 1997 Jun;15(8):849-52. doi: 10.1016/s0264-410x(96)00267-8. Vaccine. 1997. PMID: 9234531

7

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. Davis HL, et al. J Immunol. 1998 Jan 15;160(2):870-6. J Immunol. 1998. PMID: 9551923

8

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

McCluskie MJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. J Immunol. 1998 Nov 1;161(9):4463-6. J Immunol. 1998. PMID: 9794366

9

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. Brazolot Millan CL, et al. Among authors: davis hl. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8. doi: 10.1073/pnas.95.26.15553. Proc Natl Acad Sci U S A. 1998. PMID: 9861007 Free PMC article.

10

Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Mol Med. 1999 May;5(5):287-300. Mol Med. 1999. PMID: 10390545 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters